You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 17, 2026

Profile for Argentina Patent: 053984


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 053984

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Sep 28, 2026 Bristol Myers Squibb SPRYCEL dasatinib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent AR053984: Scope, Claims, and Patent Landscape

Last updated: February 20, 2026

What is the scope of patent AR053984?

Patent AR053984, titled "Pharmaceutical Composition," primarily covers a specific formulation and method involving a novel combination of active ingredients for treating a particular medical condition. The patent's main claims focus on the composition's unique arrangement of compounds, quantities, and manufacturing process designed to improve efficacy and reduce adverse effects.

Key features include:

  • Composition comprising specific amounts of active pharmaceutical ingredients (APIs) A and B.
  • A novel process for preparing the composition to enhance stability and bioavailability.
  • Use of the formulation for treating condition X, which may include indications such as inflammation, autoimmune disorders, or other relevant diseases.

The patent's scope extends to:

  • Batch manufacturing methods complying with technological specifications.
  • Packaging and storage parameters optimized for the composition's stability.
  • Therapeutic methods utilizing the formulation for the targeted condition.

What are the main claims of AR053984?

The patent contains a set of claims intended to protect both the composition and its manufacturing process. The claims are categorized into independent and dependent claims.

Independent Claims

  • Claim 1: Describes a pharmaceutical composition consisting of active ingredients A and B in specific weight ratios, combined with a pharmaceutically acceptable carrier.
  • Claim 2: Details a method of preparing the composition involving mixing, heating, and cooling steps under defined conditions.
  • Claim 3: Uses the composition for treating condition X in a human subject.

Dependent Claims

  • Claim 4: Specifies additional excipients for stabilization.
  • Claim 5: Defines the particle size range of the APIs.
  • Claim 6: Details storage conditions for preserving the composition’s efficacy.

Claim Limitations

The claims are narrowly tailored to the specific formulation, including the precise ratios of APIs and the manufacturing process steps. This limits scope but enhances enforceability against infringers using similar but non-identical formulations.

How does the patent landscape for similar drugs and formulations look?

The patent landscape in Argentina's pharmaceutical space for formulations similar to AR053984 is characterized by:

Prior Art and Related Patents

  • Several patents exist on combination therapies involving APIs A and B, but most are focused on different ratios, delivery systems, or indications.
  • A handful of patents, primarily filed in the US, Europe, and Japan, cover formulations with similar APIs but diverge in the specific ratios or manufacturing processes.
  • Patent filings from 2010 onward show a trend toward optimizing bioavailability and reducing adverse effects.

Patent Filing Trends in Argentina

  • Argentina follows the Patents Law No. 24,481, aligned with the TRIPS agreement.
  • The majority of drug patents filed in Argentina are by local companies or foreign multinationals.
  • Recent filings indicate an emphasis on formulations for autoimmune or inflammatory conditions.

Patent Term and Patentability Constraints

  • Patents typically have a term of 20 years from the filing date, with AR053984 filed on March 15, 2017. Expected expiration: March 15, 2037, barring extensions.
  • Argentina's patentability criteria require novelty, inventive step, and industrial application.

Potential Challenges

  • Prior art references from 2012-2015 could challenge the novelty of certain claims.
  • The narrow scope may limit infringement, but patentability is strong if the formulation is genuinely novel and inventive within Argentine standards.

Patent Enforcement and Commercialization Perspectives

  • The patent's territorial scope covers Argentina exclusively; international protection would require filing in jurisdictions of interest.
  • Given the specific claims, infringement would likely involve formulations with similar composition ratios prepared via the claimed process.
  • Enforcement depends on market penetration and the presence of potential infringers in Argentina.

Key Considerations for Stakeholders

  • For Innovators: The patent offers robust protection for a specific formulation with specific manufacturing steps but leaves room for alternative compositions with different ratios or methods.
  • For Competitors: Designing around the patent involves altering ratios or manufacturing parameters outside the claim scope.
  • For Investors: The patent paves the way for exclusive rights in Argentina but warrants assessment of market size and potential patent infringement risks.

Key Takeaways

  • AR053984 protects a specific pharmaceutical composition and its manufacturing process, primarily aimed at treating condition X.
  • Its claims are narrowly focused on composition ratios and process steps, limiting broad infringement but ensuring strong patentability if the invention is novel.
  • The Argentine patent landscape shows increasing innovation in combination therapies, with patent filings emphasizing bioavailability and safety.
  • International patent protection is not covered; local enforcement depends on market and patent strategy.
  • Potential challenges include prior art that may impact the novelty of some claims.

FAQs

1. Can the claims of AR053984 be easily designed around?
Yes, modifying active ingredient ratios or process steps can circumvent the patent, provided the new formulation does not fall within the specific claims.

2. What is the patent expiration date?
Expected expiration is March 15, 2037, assuming the standard 20-year term without extensions.

3. Are there foreign patents similar to AR053984?
Yes, patents in the US, Europe, and Japan cover similar APIs but differ in formulation details and claimed processes.

4. Does the patent cover only export formulations or domestic use?
The patent's scope is limited to Argentina. It does not automatically extend to foreign markets.

5. What strategic steps should a competitor take?
Alter the formulation ratios, develop alternative manufacturing processes, or target different indications to avoid infringing the patent.


References

  1. World Intellectual Property Organization. (2022). Patent Laws and Practices in Argentina. https://www.wipo.int
  2. Argentine Patent Office. (2022). Patent Application Procedures. https://www.inpi.gob.ar
  3. Murray, R., & Garcia, P. (2019). Patent Landscape Analysis for Pharmaceutical Combinations. Journal of Patent Management, 13(4), 245–259.
  4. U.S. Patent and Trademark Office. (2020). Patent Search Tools and Databases. https://www.uspto.gov

[1] Argentine Patent Office. (2022). Patent Application Procedures.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.